Scholarlink

<p>We evaluated brentuximab vedotin (BV) as maintenance therapy after autologous stem cell transplantation (ASCT) in 353 patients with relapsed/refractory Hodgkin lymphoma (HL). Of these, 52.6% received BV prior to ASCT. The five-year overall survival (OS) and progression-free survival (PFS) from the start of BV maintenance were 85.1% and 69.9%, respectively. Multivariable analysis revealed that age at ASCT (HR 1.17, <i>P</i> = 0.037), disease status (HR 3.61, <i>P</i> = 0.002), and BV treatment before ASCT (HR 0.40, <i>P</i> = 0.033) significantly impacted OS. Disease status at ASCT was the only factor significantly associated with PFS (HR 3.09, <i>p</i> &lt; 0.001) and relapse risk (HR 3.33, <i>p</i> &lt; 0.001). Although a trend toward improved PFS (HR 0.59, <i>p</i> = 0.053) and lower relapse risk (HR 0.57, <i>p</i> = 0.051) was observed in patients treated with BV before ASCT, the data were not statistically significant. Patients in complete remission (CR) at ASCT showed similar 2-year OS (94.6% vs. 99.2%, <i>P</i> = 0.3) and PFS (84.6% vs. 89%, <i>P</i> = 0.3) regardless of BV pre-transplant. In those not in CR, OS (83.1% vs. 93.6%, <i>P</i> = 0.076) and PFS (51.5% vs. 75.3%, <i>P</i> = 0.039) were higher in those previously treated with BV. This large study emphasizes BV maintenance post-ASCT, even in patients pre-treated with BV, ang highlights disease status as a key prognostic factor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group

  • 期刊论文

  • 发表日期：

    2025年4月15日

查看全文
  • Carmen Martínez,
  • Irma Khvedelidze,
  • Mathilde Fekom,
  • Benedicte Deau Fischer,
  • Amira Marouf,
  • Hervé Ghesquières,
  • Luc-Mathieu Fornecker,
  • Francesco Merli,
  • Piero Maria Stefani,
  • Fulvio Massaro,
  • Barbara Botto,
  • Burhan Ferhanoğlu,
  • Olga Meltem Akay,
  • Murat Özbalak,
  • Manuel Espeso de Haro,
  • Samuel Romero,
  • Jaques-Emmanuel Galimard,
  • Bertram Glass,
  • Ali Bazarbachi,
  • Anna Sureda

摘要

We evaluated brentuximab vedotin (BV) as maintenance therapy after autologous stem cell transplantation (ASCT) in 353 patients with relapsed/refractory Hodgkin lymphoma (HL). Of these, 52.6% received BV prior to ASCT. The five-year overall survival (OS) and progression-free survival (PFS) from the start of BV maintenance were 85.1% and 69.9%, respectively. Multivariable analysis revealed that age at ASCT (HR 1.17, P = 0.037), disease status (HR 3.61, P = 0.002), and BV treatment before ASCT (HR 0.40, P = 0.033) significantly impacted OS. Disease status at ASCT was the only factor significantly associated with PFS (HR 3.09, p < 0.001) and relapse risk (HR 3.33, p < 0.001). Although a trend toward improved PFS (HR 0.59, p = 0.053) and lower relapse risk (HR 0.57, p = 0.051) was observed in patients treated with BV before ASCT, the data were not statistically significant. Patients in complete remission (CR) at ASCT showed similar 2-year OS (94.6% vs. 99.2%, P = 0.3) and PFS (84.6% vs. 89%, P = 0.3) regardless of BV pre-transplant. In those not in CR, OS (83.1% vs. 93.6%, P = 0.076) and PFS (51.5% vs. 75.3%, P = 0.039) were higher in those previously treated with BV. This large study emphasizes BV maintenance post-ASCT, even in patients pre-treated with BV, ang highlights disease status as a key prognostic factor.